Mixtard 30 Flexpen (Insulin Human)

Insulin human mimics the body’s natural insulin by binding to insulin receptors on muscle, fat and liver cells. This activates intracellular pathways that increase glucose uptake, promote glycogen synthesis, and suppress hepatic glucose production, thereby lowering circulating blood‑sugar levels.

The dose is individualized by the prescribing healthcare professional based on factors such as the patient’s current blood‑glucose readings, carbohydrate intake, body weight, renal function, and overall treatment goals. Patients should follow the prescriber’s instructions and adjust only under medical guidance.

Insulin is generally considered the treatment of choice for diabetes in pregnancy because it does not cross the placenta in significant amounts. However, use of Mixtard 30 Flexpen should be under strict medical supervision, and the benefits must outweigh any potential risks. Breastfeeding mothers should also consult their clinician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Mixtard 30 Flexpen is a premixed insulin containing 30% rapid‑acting and 70% intermediate‑acting components, offering a convenient single‑injection regimen for many patients. Compared with basal‑only insulins, it provides prandial coverage, but it is less flexible than basal‑bolus regimens that use separate rapid‑acting and long‑acting products.

Store the pen at 2‑8 °C (refrigerated) in its original carton, protected from light. Do not freeze or shake the device. Once in use, it may be kept at room temperature (up to 30 °C) for a maximum of 28 days, after which it should be discarded.

The pen is designed for subcutaneous injection. After selecting the prescribed dose, the user inserts a new needle, primes the pen if required, and injects into the abdomen, thigh, or upper arm at a 90° angle. Injection sites should be rotated to reduce lipodystrophy risk.

The most critical risk is severe hypoglycemia, which can cause confusion, seizures, or loss of consciousness. Allergic reactions, including anaphylaxis, are rare but require immediate medical attention. Persistent unexplained weight gain or edema may also signal the need for dose reassessment.

Patients with a known hypersensitivity to insulin human or any excipients in the formulation should avoid its use. It is also contraindicated in individuals experiencing hypoglycemia until the condition is resolved, and in those for whom a different insulin regimen is clinically more appropriate.